U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07417215) titled 'The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEF' on Jan. 26.
Brief Summary: Heart failure is the most common cause of death of patients on chronic hemodialysis treatment, and to date there is no effective therapy for the treatment of this comorbidity in this group of patients. The most common form of heart failure in these groups of patients is heart failure with preserved ejection fraction (HFpEF). As a new therapy for heart failure, a new group of drugs called angiotensin receptor and neprilysin inhibitors (ARNI) has been imposed, whose representative is the drug sacubitril/vals...